Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm

We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier: NCT02091...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Yusuke, Yoshimoto, Takuya, Namai, Tomoyuki, Asakawa, Takashi, Kawakami, Satoe, Gower-Page, Craig, Reyes-Rivera, Irmarie, Patel, Arisha, Nakamura, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225680/
https://www.ncbi.nlm.nih.gov/pubmed/35649212
http://dx.doi.org/10.1200/CCI.22.00022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225680/
https://www.ncbi.nlm.nih.gov/pubmed/35649212
http://dx.doi.org/10.1200/CCI.22.00022

Ejemplares similares